EBS News and Press, Emergent Biosolutions Inc. From 05/19/22

Indaptus Therapeutics (INDP) +22% on FDA nod to begin phase 1 trial of Decoy20 for solid tumors. Zealand Pharma (ZEAL) +19% announces positive results from phase 3 trial of dasiglucagon in pediatric patients with congenital hyperinsulinism.  CBAK Energy Technology (CBAT)&#...

Wall Street finished with a mixed performance on Monday, as the major averages wound their way through another uncertain session. The S&P 500 and Nasdaq lost ground, while the Dow posted a fractional gain. While most market segments ended the day lower, the energy sector remained a source...

A poorly received decision from the management team at Chimerix (NASDAQ: CMRX) , a biopharmaceutical company, sent its stock price into a nosedive on Monday morning. Investors furious about the sale of Tembexa for an uncertain sum and the company's plans for that cash infusion have ...

Chimerix's (NASDAQ:CMRX) stock fell ~37% premarket May 16 after Emergent BioSolutions (NYSE:EBS) said it was acquiring exclusive worldwide rights to Chimerix's smallpox antiviral Tembexa. Under the agreement, Emergent will pay Chimerix $225M upfront in cash upon closing and up ...

Expands and further diversifies Emergent’s medical countermeasures portfolio with the addition of a small molecule therapeutic addressing a high priority public health threat Transaction to be funded with currently available funds; Expected to be accretive beginning with ...

GAITHERSBURG, Md., May 12, 2022 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced today that its 2022 Annual Meeting of Stockholders will be held in a virtual-only format via live audio webcast on Thursday, May 26, 2022 at 9:00 AM EDT. HOW TO PARTICIPATE IN THE VI...

Contract vaccine manufacturer Emergent BioSolutions (NYSE:EBS) was forced to destroy 400M doses of COVID-19 vaccine due to contamination issues, a figure far higher than previously disclosed. In a report from the House Oversight and Reform Committee, a communication from an Emergent quality c...

Image source: The Motley Fool. Emergent BioSolutions (NYSE: EBS) Q1 2022 Earnings Call Apr 28, 2022 , 5:00 p.m. ET Operator Continue reading For further details see: Emergent BioSolutions (EBS) Q1 2022 Earnings Call Transcript

The following slide deck was published by Emergent BioSolutions Inc. in conjunction with their 2022 Q1 earnings call. For further details see: Emergent BioSolutions Inc. 2022 Q1 - Results - Earnings Call Presentation

Emergent BioSolutions (NYSE:EBS) trades lower during the day's trade after Cowen lowered price target to $30 from $40 while maintaining its Market Perform rating on the shares. Analyst Boris Peaker noted the anthrax vaccine and Narcan revenues were ahead of guidance but Narcan is likely to sh...